MD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pediatrix Medical Group Inc (MD) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the technical indicators show some bullish trends, the lack of strong positive catalysts, neutral trading sentiment, and recent analyst downgrades suggest a cautious approach. The financial performance shows mixed results, with revenue declining but net income and EPS improving. Given the uncertainties and lack of compelling signals, holding the stock for now seems more prudent.
The technical indicators show a mildly bullish trend. The MACD histogram is positive at 0.12, indicating bullish momentum, but it is contracting. The RSI is neutral at 56.813, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 21.23, with resistance at 21.941 and support at 20.519.
Net income increased by 10.51% YoY in Q4
EPS improved by 11.11% YoY.
Gross margin remained stable at 100%.
Revenue declined by 1.71% YoY in Q4
Analysts have lowered price targets recently, citing weaker-than-expected volumes and ACA-related uncertainties.
No significant news or event-driven catalysts in the past week.
Hedge fund and insider trading sentiment is neutral, with no significant activity.
In Q4 2025, revenue dropped by 1.71% YoY to $493.77 million. However, net income increased by 10.51% YoY to $33.68 million, and EPS rose by 11.11% YoY to 0.4. Gross margin remained flat at 100%.
Analysts have recently downgraded their price targets for Pediatrix Medical Group. UBS lowered its target to $22 from $23, Deutsche Bank reduced it to $19 from $21, and Truist cut it to $21 from $24. All analysts maintained a Neutral or Hold rating, citing weaker volumes and ACA-related uncertainties.
